Evolent Health Inc. (NYSE:EVH) – Equities researchers at SunTrust Banks raised their FY2016 earnings estimates for Evolent Health in a report issued on Monday. SunTrust Banks analyst S. Draper now forecasts that the firm will earn ($0.82) per share for the year, up from their previous estimate of ($0.83). SunTrust Banks also issued estimates for Evolent Health’s Q4 2016 earnings at ($0.19) EPS, FY2017 earnings at ($0.29) EPS and FY2018 earnings at $0.20 EPS.

Evolent Health (NYSE:EVH) last issued its earnings results on Wednesday, November 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The firm had revenue of $60.20 million for the quarter, compared to the consensus estimate of $58.35 million. Evolent Health had a negative net margin of 69.04% and a negative return on equity of 5.54%. The business’s revenue was up 39.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.16) earnings per share.

Earnings History and Estimates for Evolent Health (NYSE:EVH)

EVH has been the subject of a number of other reports. Canaccord Genuity reiterated a “buy” rating and issued a $31.00 target price on shares of Evolent Health in a research note on Sunday, November 13th. Leerink Swann set a $24.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a research note on Monday. Jefferies Group assumed coverage on shares of Evolent Health in a research note on Tuesday, July 26th. They issued a “buy” rating and a $28.00 target price for the company. FBR & Co lifted their target price on shares of Evolent Health from $24.00 to $26.00 and gave the stock an “outperform” rating in a research note on Friday, August 5th. Finally, Zacks Investment Research upgraded shares of Evolent Health from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Tuesday, October 11th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $27.83.

Shares of Evolent Health (NYSE:EVH) traded down 0.97% on Wednesday, hitting $20.45. 116,246 shares of the stock traded hands. The stock’s market cap is $1.39 billion. The stock’s 50 day moving average price is $21.48 and its 200 day moving average price is $20.71. Evolent Health has a 52-week low of $8.14 and a 52-week high of $26.84.

In other Evolent Health news, Director Michael D’amato purchased 10,000 shares of Evolent Health stock in a transaction on Monday, November 14th. The stock was bought at an average cost of $17.18 per share, with a total value of $171,800.00. Following the transaction, the director now owns 18,183 shares of the company’s stock, valued at approximately $312,383.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Board Co Advisory sold 317,712 shares of the firm’s stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $22.50, for a total transaction of $7,148,520.00. Following the transaction, the insider now directly owns 4,128,167 shares of the company’s stock, valued at $92,883,757.50. The disclosure for this sale can be found here. Company insiders own 8.85% of the company’s stock.

Several institutional investors have recently bought and sold shares of EVH. Blair William & Co. IL raised its position in Evolent Health by 205.5% in the second quarter. Blair William & Co. IL now owns 341,570 shares of the company’s stock valued at $6,558,000 after buying an additional 229,748 shares during the period. Swiss National Bank raised its position in Evolent Health by 90.2% in the second quarter. Swiss National Bank now owns 32,900 shares of the company’s stock valued at $632,000 after buying an additional 15,600 shares during the period. Ameriprise Financial Inc. purchased a new position in Evolent Health during the second quarter valued at $1,565,000. Systematic Financial Management LP purchased a new position in Evolent Health during the second quarter valued at $3,480,000. Finally, Schwab Charles Investment Management Inc. raised its position in Evolent Health by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,784 shares of the company’s stock valued at $822,000 after buying an additional 504 shares during the period. 37.14% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “SunTrust Banks Weighs in on Evolent Health Inc.’s FY2016 Earnings (EVH)” was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2016/11/23/suntrust-banks-weighs-in-on-evolent-health-inc-s-fy2016-earnings-evh.html.

About Evolent Health

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

5 Day Chart for NYSE:EVH

Receive News & Stock Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related stocks with our FREE daily email newsletter.